Improving Anticoagulant Therapy Through Warfarin Metabolite Profiling

Completed

Conditions studied: Stable Target INR

In brief

Clinically relevant biomarkers for warfarin identified in this study will provide crucial leads for subsequent studies to assess their predictive value during anticoagulant therapy. This knowledge will aid stratifying risk among patients to improve therapeutic outcomes and decrease adverse drug events and associated health care costs. Collectively, these efforts will provide a critical foundation for future research using a metabolite biomarker strategy in a clinical setting to revolutionize warfarin therapy. Through its application, a real-time assessment of warfarin metabolism for each patient could lead to a truly personalized dosing strategy and improve patient safety for this life-saving drug.

Key facts

Study ID
NCT01964794
Run by
University of Arkansas
People needed
60
Starts
2012-05-01
Expected to finish
2016-10-01
Last updated by the study team
2016-10-07

Who can join

Age: 60 and older, up to 69. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.